These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 36400033)

  • 1. POLθ processes ssDNA gaps and promotes replication fork progression in BRCA1-deficient cells.
    Schrempf A; Bernardo S; Arasa Verge EA; Ramirez Otero MA; Wilson J; Kirchhofer D; Timelthaler G; Ambros AM; Kaya A; Wieder M; Ecker GF; Winter GE; Costanzo V; Loizou JI
    Cell Rep; 2022 Nov; 41(9):111716. PubMed ID: 36400033
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mechanisms of synthetic lethality between BRCA1/2 and 53BP1 deficiencies and DNA polymerase theta targeting.
    Ronson GE; Starowicz K; Anthony EJ; Piberger AL; Clarke LC; Garvin AJ; Beggs AD; Whalley CM; Edmonds MJ; Beesley JFJ; Morris JR
    Nat Commun; 2023 Nov; 14(1):7834. PubMed ID: 38030626
    [TBL] [Abstract][Full Text] [Related]  

  • 3. POLθ prevents MRE11-NBS1-CtIP-dependent fork breakage in the absence of BRCA2/RAD51 by filling lagging-strand gaps.
    Mann A; Ramirez-Otero MA; De Antoni A; Hanthi YW; Sannino V; Baldi G; Falbo L; Schrempf A; Bernardo S; Loizou J; Costanzo V
    Mol Cell; 2022 Nov; 82(22):4218-4231.e8. PubMed ID: 36400008
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genetic separation of Brca1 functions reveal mutation-dependent Polθ vulnerabilities.
    Krais JJ; Glass DJ; Chudoba I; Wang Y; Feng W; Simpson D; Patel P; Liu Z; Neumann-Domer R; Betsch RG; Bernhardy AJ; Bradbury AM; Conger J; Yueh WT; Nacson J; Pomerantz RT; Gupta GP; Testa JR; Johnson N
    Nat Commun; 2023 Nov; 14(1):7714. PubMed ID: 38001070
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Polymerase theta-helicase promotes end joining by stripping single-stranded DNA-binding proteins and bridging DNA ends.
    Schaub JM; Soniat MM; Finkelstein IJ
    Nucleic Acids Res; 2022 Apr; 50(7):3911-3921. PubMed ID: 35357490
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Single-Stranded DNA Gap Accumulation Is a Functional Biomarker for USP1 Inhibitor Sensitivity.
    da Costa AA; Somuncu O; Ravindranathan R; Mukkavalli S; Martignetti DB; Nguyen H; Jiao Y; Lamarre BP; Sadatrezaei G; Moreau L; Liu J; Iyer DR; Lazaro JB; Shapiro GI; Parmar K; D'Andrea AD
    Cancer Res; 2024 Oct; 84(20):3435-3446. PubMed ID: 38885312
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novobiocin blocks nucleic acid binding to Polθ and inhibits stimulation of its ATPase activity.
    Syed A; Filandr F; Patterson-Fortin J; Bacolla A; Ravindranathan R; Zhou J; McDonald DT; Albuhluli ME; Verway-Cohen A; Newman JA; Tsai MS; Jones DE; Schriemer DC; D'Andrea AD; Tainer JA
    Nucleic Acids Res; 2023 Oct; 51(18):9920-9937. PubMed ID: 37665033
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Loss of nuclear DNA ligase III reverts PARP inhibitor resistance in BRCA1/53BP1 double-deficient cells by exposing ssDNA gaps.
    Paes Dias M; Tripathi V; van der Heijden I; Cong K; Manolika EM; Bhin J; Gogola E; Galanos P; Annunziato S; Lieftink C; Andújar-Sánchez M; Chakrabarty S; Smith GCM; van de Ven M; Beijersbergen RL; Bartkova J; Rottenberg S; Cantor S; Bartek J; Ray Chaudhuri A; Jonkers J
    Mol Cell; 2021 Nov; 81(22):4692-4708.e9. PubMed ID: 34555355
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sequential requirements for distinct Polθ domains during theta-mediated end joining.
    Fijen C; Drogalis Beckham L; Terino D; Li Y; Ramsden DA; Wood RD; Doublié S; Rothenberg E
    Mol Cell; 2024 Apr; 84(8):1460-1474.e6. PubMed ID: 38640894
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Polθ Inhibition: An Anticancer Therapy for HR-Deficient Tumours.
    Barszczewska-Pietraszek G; Drzewiecka M; Czarny P; Skorski T; Śliwiński T
    Int J Mol Sci; 2022 Dec; 24(1):. PubMed ID: 36613762
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Polθ: emerging synthetic lethal partner in homologous recombination-deficient tumors.
    Bazan Russo TD; Mujacic C; Di Giovanni E; Vitale MC; Ferrante Bannera C; Randazzo U; Contino S; Bono M; Gristina V; Galvano A; Perez A; Badalamenti G; Russo A; Bazan V; Incorvaia L
    Cancer Gene Ther; 2024 Nov; 31(11):1619-1631. PubMed ID: 39122831
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structural basis for a Polθ helicase small-molecule inhibitor revealed by cryo-EM.
    Ito F; Li Z; Minakhin L; Chandramouly G; Tyagi M; Betsch R; Krais JJ; Taberi B; Vekariya U; Calbert M; Skorski T; Johnson N; Chen XS; Pomerantz RT
    Nat Commun; 2024 Aug; 15(1):7003. PubMed ID: 39143110
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Excess Polθ functions in response to replicative stress in homologous recombination-proficient cancer cells.
    Goullet de Rugy T; Bashkurov M; Datti A; Betous R; Guitton-Sert L; Cazaux C; Durocher D; Hoffmann JS
    Biol Open; 2016 Oct; 5(10):1485-1492. PubMed ID: 27612511
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FANCD2 Maintains Fork Stability in BRCA1/2-Deficient Tumors and Promotes Alternative End-Joining DNA Repair.
    Kais Z; Rondinelli B; Holmes A; O'Leary C; Kozono D; D'Andrea AD; Ceccaldi R
    Cell Rep; 2016 Jun; 15(11):2488-99. PubMed ID: 27264184
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular basis of microhomology-mediated end-joining by purified full-length Polθ.
    Black SJ; Ozdemir AY; Kashkina E; Kent T; Rusanov T; Ristic D; Shin Y; Suma A; Hoang T; Chandramouly G; Siddique LA; Borisonnik N; Sullivan-Reed K; Mallon JS; Skorski T; Carnevale V; Murakami KS; Wyman C; Pomerantz RT
    Nat Commun; 2019 Sep; 10(1):4423. PubMed ID: 31562312
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting Polymerase Theta (POLθ) for Cancer Therapy.
    Patterson-Fortin J; D'Andrea AD
    Cancer Treat Res; 2023; 186():285-298. PubMed ID: 37978141
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The endonuclease EEPD1 mediates synthetic lethality in RAD52-depleted BRCA1 mutant breast cancer cells.
    Hromas R; Kim HS; Sidhu G; Williamson E; Jaiswal A; Totterdale TA; Nole J; Lee SH; Nickoloff JA; Kong KY
    Breast Cancer Res; 2017 Nov; 19(1):122. PubMed ID: 29145865
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Small Molecules Targeting DNA Polymerase Theta (POLθ) as Promising Synthetic Lethal Agents for Precision Cancer Therapy.
    Pismataro MC; Astolfi A; Barreca ML; Pacetti M; Schenone S; Bandiera T; Carbone A; Massari S
    J Med Chem; 2023 May; 66(10):6498-6522. PubMed ID: 37134182
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Error-Prone Replication through UV Lesions by DNA Polymerase θ Protects against Skin Cancers.
    Yoon JH; McArthur MJ; Park J; Basu D; Wakamiya M; Prakash L; Prakash S
    Cell; 2019 Mar; 176(6):1295-1309.e15. PubMed ID: 30773314
    [TBL] [Abstract][Full Text] [Related]  

  • 20. DNA polymerase theta-mediated DNA repair is a functional dependency and therapeutic vulnerability in DNMT3A deficient leukemia cells.
    Le BV; Vekariya U; Toma MM; Nieborowska-Skorska M; Caron MC; Gozdecka M; Haydar Z; Walsh M; Ghosh J; Vaughan-Williams E; Podszywalow-Bartnicka P; Kukuyan AM; Ziolkowska S; Hadzijusufovic E; Chandramouly G; Piwocka K; Pomerantz R; Vassiliou GS; Huntly BJ; Valent P; Bellacosa A; Masson JY; Gupta GP; Challen GA; Skorski T
    bioRxiv; 2024 Sep; ():. PubMed ID: 39411165
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.